Skip to main content
Utility Menu
Investors
Newsroom
Contact Us
Regional Navigation
Global Sites
Switzerland
Deutsch
English
Français
Italiano
UK
English
United States
English
Toggle Menu Button
Utility Menu
Investors
Newsroom
Contact Us
Regional Navigation
Global Sites
Switzerland
Deutsch
English
Français
Italiano
UK
English
United States
English
Social Links
Twitter
LinkedIn
Instagram
Facebook
Main navigation
Our Disease Areas
Duchenne Muscular Dystrophy
Limb-girdle Muscular Dystrophy
Charcot-Marie-Tooth Disease
Our Science
Gene Therapy Engine
RNA Platform
Gene Editing
Manufacturing
Strategic Partnerships
Our Products & Pipeline
Products
Pipeline
Clinical Trials
Treatment Access
About Us
Leadership
Patient Affairs
Corporate Responsibility
Grants & Giving
Global Locations
Contact Us
Join Us
Career Opportunities
Toggle Menu Button
Search
Giving thanks for our employees’ incredible dedication: Six employees explain why Sarepta is a Top Place to Work
Expanding access to newborn screening for those with rare diseases
From art to science: How one Sarepta scientist brings arts into the lab
Advocacy community unites to support families
How Sarepta infused its corporate brand with urgency and optimism on behalf of patients
Patiently waiting
Corporate Responsibility
Seeing hope at genetic medicine's frontier: Meet Stefanie Mason, M.D.
Sarepta Therapeutics Announces Positive Vote from U.S. FDA Advisory Committee Meeting for SRP-9001 Gene Therapy to Treat Duchenne Muscular Dystrophy
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pagination
First page
« First
Previous page
‹ Previous
…
Page
29
Page
30
Page
31
Page
32
Page
33
Page
34
Page
35
Current page
36
Page
37
Next page
Next ›
Last page
Last »